CA-170
CA-170 is an orally delivered dual inhibitor of VISTA and PD-L1. CA-170 exhibits potent rescue of proliferation and effector functions of T cells inhibited by PD-L1/L2 and VISTA with selectivity over other immune checkpoint proteins as well as a broad panel of receptors and enzymes[1][2].
Product Specifications
CAS Number
1673534-76-3
UNSPSC
12352005
Target
PD-1/PD-L1
Type
Reference compound
Related Pathways
Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Cancer
Assay Protocol
Purity
99.39
Solubility
DMSO : 28.5 mg/mL (ultrasonic; warming)
Smiles
C[C@@H](O)[C@@H](C(O)=O)NC(N[C@H](C1=NC([C@@H](N)CO)=NO1)CC(N)=O)=O
Molecular Formula
C12H20N6O7
Molecular Weight
360.32
References & Citations
[1]Pottayil Govindan Nair Sasikumar, et al. 1,2,4-oxadiazole derivatives as immunomodulators. WO2015033299A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
Polyclonal Antibody to Wingless Type MMTV Integration Site Family, Member 7A (WNT7A)
Polyclonal Antibody to Wingless Type MMTV Integration Site Family, Member 7A (WNT7A)
Polyclonal Antibody to Wingless Type MMTV Integration Site Family, Member 7A (WNT7A)
Polyclonal Antibody to Wingless Type MMTV Integration Site Family, Member 7A (WNT7A)
Lentiviral mouse Zfp947 shRNA (UAS) - Lentiviral mouse Zfp947 shRNA (UAS, RFP) (100)
